<?xml version='1.0' encoding='utf-8'?>
<document id="31807051"><sentence text="Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects."><entity charOffset="27-37" id="DDI-PubMed.31807051.s1.e0" text="Amlodipine" /><entity charOffset="64-74" id="DDI-PubMed.31807051.s1.e1" text="Omeprazole" /><pair ddi="false" e1="DDI-PubMed.31807051.s1.e0" e2="DDI-PubMed.31807051.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31807051.s1.e0" e2="DDI-PubMed.31807051.s1.e1" /></sentence><sentence text="CYP2C19 and CYP3A are the main enzymes involved in omeprazole metabolism, while CYP3A is the principal enzyme family for amlodipine biotransformation"><entity charOffset="51-61" id="DDI-PubMed.31807051.s2.e0" text="omeprazole" /><entity charOffset="121-131" id="DDI-PubMed.31807051.s2.e1" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.31807051.s2.e0" e2="DDI-PubMed.31807051.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31807051.s2.e0" e2="DDI-PubMed.31807051.s2.e1" /></sentence><sentence text=" Concomitant use of these drugs in patients with hypertension and acid-related disorders (ARD) might lead to drug-drug interaction" /><sentence text="" /><sentence text="The aim of the study was to find if adding omeprazole for treating ARD to amlodipine long-term therapy of hypertension influenced blood pressure of CYP2C19 polymorphism carriers"><entity charOffset="43-53" id="DDI-PubMed.31807051.s5.e0" text="omeprazole" /><entity charOffset="74-84" id="DDI-PubMed.31807051.s5.e1" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.31807051.s5.e0" e2="DDI-PubMed.31807051.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31807051.s5.e0" e2="DDI-PubMed.31807051.s5.e1" /></sentence><sentence text="" /><sentence text="Fifty-one patients diagnosed with hypertension and ARD were enrolled in the study" /><sentence text=" Evaluation of antihypertensive therapy was performed by office (OBPM) and ambulatory (ABPM) blood pressure monitoring" /><sentence text=" Peripheral venous blood was collected for DNA extraction and real-time polymerase chain reaction was performed for CYP2C19*2G681A (rs4244285), CYP2C19*3G636A (rs4986893) and CYP2C19*17C-806T (rs12248560) polymorphisms analysis"><entity charOffset="175-191" id="DDI-PubMed.31807051.s9.e0" text="CYP2C19*17C-806T" /></sentence><sentence text="" /><sentence text="Of 51 patients there were 21 extensive metabolizers (EMs), 18 ultrarapid metabolizers (UMs) and 12 intermediate metabolizers (IMs)" /><sentence text=" The results of OBPM showed that antihypertensive effect was significantly more pronounced in IMs compared to EMs or UMs and the average group value in the following parameters: average office systolic blood pressure (BP), dynamics of the average office systolic BP" /><sentence text=" According to dynamics of diastolic BP, the antihypertensive effect was also significantly higher in IMs than in UMs and the average group value" /><sentence text=" The results of ABPM revealed that there was a significantly more pronounced antihypertensive effect in IMs compared to all other analyzed groups according to the dynamics of both daytime systolic and 24 hr diastolic BP" /><sentence text=" The average daytime diastolic BP and its dynamics, the average 24 hr systolic BP and its dynamics were higher in IMs compared to EMs and UMs" /><sentence text="" /><sentence text="Adding omeprazole to long-term amlodipine therapy in patients with hypertension and ARD may lead to a significantly more pronounced antihypertensive effect in patients genotyped CYP2C19 IMs"><entity charOffset="7-17" id="DDI-PubMed.31807051.s17.e0" text="omeprazole" /><entity charOffset="31-41" id="DDI-PubMed.31807051.s17.e1" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.31807051.s17.e0" e2="DDI-PubMed.31807051.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31807051.s17.e0" e2="DDI-PubMed.31807051.s17.e1" /></sentence><sentence text="" /></document>